Gonadotropins and Their Association with the Risk of Prediabetes and Type 2 Diabetes in Middle-Aged Postmenopausal Women

Table 3

Association of FSH, LH, and LH/FSH ratio with metabolic disturbances.

Progression from NFG to IFG	FSH^1	FSH^2	FSH^3	FSH^4	FSH^5	FSH^6	FSH^7	FSH^8	FSH^9
OR (95% CI) per 1 SD decrease in -score of FSH	2.83^& (1.3 - 6.0)	2.88^& (1.4 - 6.1)	2.91^& (1.2 - 7.0)	2.3 (1.0 - 4.7)	2.1 (0.9 - 3.8)	2.9^& (1.4 - 6.3)	2.59^& (1.2 – 5.6)	2.49 (1.1 – 5.3)	2.82^& (1.3 – 5.9)
Progression from IFG to diabetes	FSH^1	FSH^2	FSH^3	FSH^4	FSH^5	FSH^6	FSH^7	FSH^8	FSH^9
OR (95% CI) per 1 SD decrease in -score of FSH	8.49^& (4.6 -18.0)	8.64^& (3.0 - 20.0)	5.27^& (2.8 - 10.0)	4.3^& (2.1 - 9.5)	6.2^& (2.8 - 15.1)	7.5^& (3.4 - 17.2)	8.2^& (4.3 –17.3)	8.70^& (5.1 –19.3)	8.59^& (3.2 –19.6)
Progression to HOMA-	FSH^1	FSH^2	FSH^3	FSH^4	FSH^5	FSH^6	FSH^7	FSH^8	FSH^9
OR (95% CI) per 1 SD decrease in -score of FSH	5.0^! (2.3 - 10.7)	5.2^! (2.4 - 11.4)	4.7^! (2.0 - 11.1)	4.4^& (1.9 - 10.3)	4.34^& (1.9 - 9.9)	4.3^& (1.9 - 10.0)	4.49^& (2.1 – 9.7)	4.47^& (1.8 –11.3)	4.78^! (2.3 –10.1)
Progression from NFG to IFG	LH^1	LH^2	LH^3	LH^4	LH^5	LH^6	LH^7	LH^8	LH^9
OR (95% CI) per 1 SD decrease in -score of LH	1.14 (0.7 - 2.0)	1.09 (0.6 - 2.0)	0.96 (0.5 -1.7)	1.07 (0.6 - 1.9)	1.17 (0.6 - 2.2)	1.15 (0.7 – 2.0)	1.0 (0.6 – 1.6)	1.11 (0.4 – 3.0)	1.22 (0.7 – 2.2)
Progression from IFG to diabetes	LH^1	LH^2	LH^3	LH^4	LH^5	LH^6	LH^7	LH^8	LH^9
OR (95% CI) per 1 SD decrease in -score of LH	3.5 (1.0 - 11.9)	3.54 (1.0 - 12.0)	1.15 (0.21 - 6.0)	2.8 (0.6 –12.0)	4.17 (1.0 -13.0)	3.1 (0.9 - 10.0)	3.6 (1.0 –12.7)	3.1 (0.8 –10.0)	3.60 (1.0 –12.8)
Progression to HOMA-	LH^1	LH^2	LH^3	LH^4	LH^5	LH^6	LH^7	LH^8	LH^9
OR (95% CI) per 1 SD decrease in -score of LH	2.6^& (1.4 - 4.7)	2.51^& (1.4 - 4.6)	2.05 (1.1 - 3.8)	2.2 (1.2 - 4.1)	2.2^& (1.2 - 4.1)	2.45^& (1.2 - 5.0)	2.56^& (1.3 – 5.0)	2.17 (1.1 – 4.4)	2.69! (1.5 – 4.8)
Progression from NFG to IFG	LH/FSH^1	LH/FSH^2	LH/FSH^3	LH/FSH^4	LH/FSH^5	LH/FSH^6	LH/FSH^7	LH/FSH^8	LH/FSH^9
OR (95% CI) per 1 SD increase in -score of LH/FSH	2.03 (1.1 - 3.7)	2.05 (1.1 - 3,7)	1.96 (1.1 - 3.5)	1.95 (1.1 - 3.5)	1.38 (0.7 - 2.9)	2.1 (1.1 – 3.8)	1.96 (1.1 – 3.6)	1.94 (0.8 – 3.1)	1.98 (1.1 – 3.6)
Progression from IFG to diabetes	LH/FSH^1	LH/FSH^2	LH/FSH^3	LH/FSH^4	LH/FSH^5	LH/FSH^6	LH/FSH^7	LH/FSH^8	LH/FSH^9
OR (95% CI) per 1 SD increase in -score of LH/FSH	1.16 (0.6 - 2.2)	1.25 (0.6 - 2.5)	1.64 (0.6 - 3.8)	1.7 (0.7 - 4.2)	0.93 (0.4 - 2.0)	1.15 (0.6 – 2.2)	1.2 (0.6 – 2.3)	1.45 (0.6 – 3.5)	1.17 (0.6 – 2.2)
Progression to HOMA-	LH/FSH^1	LH/FSH^2	LH/FSH^3	LH/FSH^4	LH/FSH^5	LH/FSH^6	LH/FSH^7	LH/FSH^8	LH/FSH^9
OR (95% CI) per 1 SD increase in -score of LH/FSH	1.55 (1.0 - 2.5)	1.39 (0.9 - 2.2)	1.39 (0.8 - 2.3)	1.4 (0.9 - 2.4)	1.33 (0.8 - 2.3)	1.31 (0.7 - 2.3)	1.38 (0.8 – 2.3)	1.58 (0.9 – 2.7)	1.50 (0.9 – 2.4)

Model 1 crude model; model 2 crude model adjusted for age; model 3 crude model adjusted for WC; model 4 crude model adjusted for BMI; model 5 crude model adjusted for CRP; model 6 crude model adjusted for TG; model 7 crude model adjusted for HDL; model 8 crude model adjusted for systolic blood pressure; model 9 crude model adjusted for 17beta-estradiol. level of Wald statistic,^!, ^&, for all models achieved that statistical goodness-of-fit according to log-likelihood statistics.